Psoriatic Arthritis

Data presented at EULAR 2025 showcased Tremfya's efficacy as the only IL-23 inhibitor to demonstrate inhibition of this nature in psoriatic arthritis.

At the 2025 EULAR meeting, UCB presented new 3-year data on bimekizumab for PsA.

The National Psoriasis Foundation Seal of Recognition program has expanded to prescription drugs, making roflumilast the first to achieve the indication.

Tremfya is the first IL-23 inhibitor to significantly improve both symptoms and structural damage in active psoriatic arthritis.

Unlike biologics, nonbiologic systemic therapies showed a neutral or slightly increased cardiovascular risk, raising concerns about their long-term safety.

A study reveals that biologics targeting IL-12, IL-23, and IL-17 lower the risk of serious infections in older adults with psoriatic disease.

According to a poster from AAD, the National Psoriasis Foundation’s treatment goals were used as a benchmark to determine the risk of developing psoriatic arthritis after initiating biologics.

Ustekinumab-kfce is available for the treatment of chronic autoimmune conditions like Crohn’s disease, ulcerative colitis, and plaque psoriasis.

Advances in biologics, JAK inhibitors, and PDE4 inhibitors provide personalized options for psoriasis management.

Researchers found that PsA patients prioritize fatigue, sleep issues, and uncertainty, often ranking them higher than doctors do.

Effective PsA management requires balancing clinical goals with patient-reported challenges like fatigue and daily disruptions.

Deucravacitinib achieved ACR20 response in patients with PsA at week 16, with a safety profile consistent with previous studies.

The FDA recently approved Yesintek for treating psoriasis, psoriatic arthritis, and IBD, with a 2025 launch expected.

2-year data show 75.7% of TNFi-IR patients maintained ACR50, 80.6% achieved PASI100, and pain and fatigue improvements were sustained.

The new delivery systems for bimekizumab-bkzx represent an upgrade over previous 1 mL options, reducing the frequency of injections required.

The study design emphasizes elevated endpoints, particularly joint health, ensuring that the most relevant outcomes are prioritized for patient care.

Otulfi from Formycon and Fresenius Kabi was approved simultaneously in the US and the European Union. In the US, it will launch in February 2025.

Mease, the lead investigator on the trial, spoke about comparing varying mechanisms of action, primary and secondary endpoints, and how the results of BE BOLD could affect treatment choices.

This marks the first head-to-head trial of an IL-17A/F inhibitor against an IL-23 inhibitor in psoriatic arthritis treatment.

Bimzelx was also approved for non-radiographic axial spondyloarthritis and ankylosing spondylitis.

Brenda Kong-Tunac, a patient with PsO, PsA, and skin of color, shares her experiences.

Researchers behind the phase 3 studies gave pearls into the study methods, results, and what is up next.

Pyzchiva will be commercialized by Sandoz in the United States.

Gottlieb reviews her lecture from the Society for Investigative Dermatology Annual Meeting.

The phase 3 IZAR program will evaluate the efficacy and safety of sonelokimab in patients with psoriatic arthritis for a 1 year duration.

Upadacitinib is now available as a tablet or an oral solution for patients 2 years and older with pJIA as well as PsA.

This research indicates that psychological well-being serves a key role in the management of psoriatic disease.

Last week, the FDA approved an sBLA for Sandoz’s adalimumab-adaz in various strengths, including 10 mg/0.1 mL, 20 mg/0.2 mL, and 80 mg/0.8 mL.

Adalimumab-adbm is now approved for use in various indications, including psoriasis, psoriatic arthritis, and hidradenitis suppurativa.

Last week, the US Food and Drug Administration approved biosimilar ustekinumab-aekn (Selarsdi; Alvotech and Teva) for psoriasis and PsA.